Medications

Mounjaro vs. Zepbound: Comparing Tirzepatide for Diabetes and Weight Loss

GLP-1 Companion · 7 min read

If you have been researching GLP-1 medications, you have likely encountered both Mounjaro and Zepbound and wondered how they differ. The straightforward answer: they contain the exact same active ingredient—tirzepatide—made by the same manufacturer, Eli Lilly. The distinction is entirely about what each is FDA-approved to treat, which has significant implications for prescribing, insurance, and cost.

Same Molecule, Different Approvals

Tirzepatide is a dual GLP-1/GIP receptor agonist administered as a once-weekly subcutaneous injection. Eli Lilly brought it to market under two separate brand names to comply with FDA regulations, which require distinct approvals for different therapeutic indications.

• Mounjaro: FDA-approved in May 2022 for the treatment of type 2 diabetes in adults.
• Zepbound: FDA-approved in November 2023 for chronic weight management in adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related condition.

Dosing Comparison

Both Mounjaro and Zepbound offer the same six dose levels and follow the same escalation schedule:

1. 2.5 mg weekly (starting dose for 4 weeks)
2. 5 mg weekly
3. 7.5 mg weekly
4. 10 mg weekly
5. 12.5 mg weekly
6. 15 mg weekly (maximum dose)

Unlike the semaglutide brands (Ozempic vs. Wegovy), where the maximum doses differ, Mounjaro and Zepbound have identical dose ranges. Your provider will escalate based on your response and tolerability regardless of which brand you are prescribed.

Insurance Coverage

Insurance is often the deciding factor in which brand a patient receives. Coverage depends heavily on your diagnosis and the specifics of your health plan.

Mounjaro Coverage

• Typically covered under pharmacy benefits for patients with a documented type 2 diabetes diagnosis.
• Most commercial insurance plans and many Medicare Part D plans include Mounjaro on their formularies.
• Prior authorization is often required, including documentation of HbA1c levels and sometimes failure of first-line therapies like metformin.

Zepbound Coverage

• Coverage for weight-loss medications is more limited across the insurance landscape.
• Some commercial plans are beginning to cover anti-obesity medications, but many still exclude them.
• Medicare Part D historically has not covered weight-loss drugs, though proposed legislation could change this.
• Employer-sponsored plans vary widely; large employers are increasingly adding obesity treatment benefits.

Cost Comparison

The list prices are comparable but not identical. Eli Lilly priced Zepbound slightly lower than Mounjaro at launch—approximately $1,060 per month versus $1,175 per month—in an effort to improve access for weight-loss patients. However, out-of-pocket costs depend entirely on your insurance.

• With good insurance coverage and a manufacturer savings card, copays can be as low as $25 per month for either brand.
• Without insurance, both medications cost over $1,000 per month.
• Some patients access tirzepatide through telehealth platforms or specialty pharmacies that negotiate lower cash prices.
• Compounded tirzepatide may be available at lower cost, but these formulations are not FDA-approved and carry additional risks.

Effectiveness: Any Difference?

Since both medications deliver the same molecule at the same doses, their clinical effectiveness is equivalent. The weight-loss and blood-sugar-lowering effects demonstrated in the SURPASS and SURMOUNT trials apply equally to both brands. The difference in trial results between the two programs primarily reflects the different patient populations studied (diabetes vs. obesity without diabetes) rather than any difference in the drug itself.

Choosing between Mounjaro and Zepbound is not a medical decision—it is a regulatory and insurance decision. The drug inside the pen is the same.

Which Should You Choose?

• If you have type 2 diabetes (with or without obesity): Mounjaro is the logical choice, as it is approved for your condition and more likely to be covered by insurance.
• If your primary concern is weight loss (without diabetes): Zepbound is the appropriate brand, assuming your insurance covers it.
• If you have both conditions: Discuss with your provider which approval pathway yields the best insurance coverage and lowest cost.
• If neither is covered by insurance: Compare cash prices, manufacturer savings programs, and telehealth options for both brands.

Can You Switch Between Mounjaro and Zepbound?

Switching between the two is straightforward since they are the same medication. A patient on Mounjaro 10 mg can transition to Zepbound 10 mg without any washout period or re-escalation. The main reason patients switch is a change in insurance coverage, diagnosis coding, or formulary status. Your provider can facilitate the transition with a new prescription and, if needed, a new prior authorization.

The Bottom Line

Mounjaro and Zepbound are the same drug—tirzepatide—with different FDA labels. Mounjaro is approved for type 2 diabetes; Zepbound is approved for weight management. The dosing is identical, the side effects are the same, and the clinical efficacy is equivalent. The practical choice between them comes down to your diagnosis, insurance plan, and cost. Work with your healthcare provider to determine which brand makes the most sense for your situation.

Sources

• Jastreboff et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. NEJM.
• Mounjaro (tirzepatide) Prescribing Information. Eli Lilly.